AHAngkana T. Huang

Angkana T. Huang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Angkana T. Huang has a total of 296 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Impact of DENV-ZIKV cross-reactivity in Southeast Asia: A modelling study in Thailand

    by Yile Shi, Abhishek Senapati, Angkana T. Huang, Hannah E. Clapham

    Dengue virus (DENV) is endemic across Southeast Asia (SEA), where a large proportion of adults have been infected. Zika virus (ZIKV) has circulated in the region for decades but the extent of transmission remains unclear. Prior infection with one virus can protect against or enhance infection with the other, but the population-level consequences are unknown. We developed an age-structured DENV-ZIKV model with nine cross-reactivity assumptions combining cross-protection and subsequent enhancement, and simulated sustained co-circulation under changing Thai demography. Through cross-reactivity, DENV strongly shaped ZIKV transmission, whereas ZIKV had little effect on DENV transmission. Under cross-protection, ZIKV transmission occurred as infrequent outbreaks without changes in long-term ZIKV burden. When prior DENV infection enhanced both ZIKV infection and symptomatic risk, this burden roughly doubled. Population ageing raised the mean age of DENV and ZIKV cases by over 20 years, more than cross-reactivity did. Simulated ZIKV case ages were closer to those reported in Thailand in 2019–2023 under enhancement of ZIKV infection and symptoms. Over half of individuals aged 15–49 years remained ZIKV-naive under all assumptions, leaving many pregnancies at risk of congenital Zika syndrome. Interpreting ZIKV case counts in SEA requires joint consideration of cross-reactivity, demographic change and case detection.

  • Open Access

    Reply to: Evidence of widespread sequencing errors in global avian influenza study

    by Dhammika Leshan Wannigama, Mohan Amarasiri, Phatthranit Phattharapornjaroen, Cameron Hurst, Charin Modchang, John Jefferson V. Besa, Kazuhiko Miyanaga, Longzhu Cui, Stefan Fernandez, Angkana T. Huang, et al.

  • Open Access

    Bridging surveillance gaps in dengue: a hierarchical model integrating mixed data sources for transmission estimation and vaccine targeting

    by Bimandra A Djaafara, Iqbal Rf Elyazar, Prima Yosephine, Asik Surya, Fadjar Sm Silalahi, Agus Handito, Burhannudin Thohir, Desfalina Aryani, Dyana Gunawan, Anzala Khoirun Nisa, et al.

    Estimating dengue force of infection (FOI) is essential for understanding transmission dynamics and targeting intervention programmes, yet surveillance data in endemic settings required for estimations are often incomplete, with varying formats. We developed a Bayesian hierarchical catalytic model that jointly fits age-stratified case data, aggregate case data, and seroprevalence surveys within a single framework, incorporating external covariates to improve parameter identifiability. Synthetic validation showed that covariates alone recovered accurate FOI point estimates even when most districts contributed only aggregate data, but did so with poorly calibrated uncertainty; anchoring the model with a single seroprevalence survey was necessary to bring credible interval coverage close to nominal. Applied to 128 districts across Java and Bali, Indonesia (2016–2024), the model revealed substantial spatial heterogeneity in FOI and reporting rates. Many districts in Java exceeded the WHO-suggested seroprevalence threshold for vaccine introduction, yet were classified as low-priority when using reported incidence as prioritisation criterion, particularly in areas with weak surveillance. Model-based seroprevalence estimation, integrating multiple data sources, offers a more consistent basis for identifying high-priority districts for vaccine introduction, and is less susceptible to surveillance bias than reported incidence.

  • Open Access

    Combining vaccination with w Mel for dengue control in Brazil

    by Emilie Finch, Angkana T. Huang, Clare McCormack, Anna Vicco, Julio Croda, Neil M. Ferguson, Ilaria Dorigatti, Henrik Salje

    Dengue virus is a severe threat to global health. Novel vaccine and Wolbachia technologies offer a potential path to dengue control; however, it remains unclear how to use these approaches in tandem. Using metapopulation transmission models, we simulated future dengue burden in Brazil. We estimated that w Mel releases in 300 municipalities could avert 12-22% of cases over the next 10 years, while a national vaccination campaign could avert 8-10% of cases in the total population and 39-45% within the vaccinated cohort. Projecting forward 40 years, we found w Mel releases would drive up the mean age of cases beyond increases due to the ageing population and increase population susceptibility to dengue. Finally, w Mel releases can help mitigate the future burden in southern Brazil where climate change is rapidly increasing dengue virus risk. These findings highlight the need to consider the two technologies in parallel to optimise efforts to combat future dengue burden.

  • Open Access

    Long-term antibody dynamics challenge the paradigm of lifelong homotypic immunity to dengue virus

    by Jair Andrade, Adrien Mitard de Girardier, Angkana T. Huang, Darunee Buddhari, Marco Hamins-Puertolas, Maria-Theresa Alera, Mary Noreen Chua, Taweewun Hunsawong, Derek A. T. Cummings, Stephen Thomas, et al.

    Immunity following infection with the four dengue virus serotypes (DENV1-4) remains difficult to define. Reports of individuals being reinfected with the same serotype challenge the paradigm that infection induces lifelong homotypic immunity. However, the frequency of these events and their importance for shaping immune profiles remain unknown. Here, we used data from three cohorts (N = 4,268 total participants) in two highly endemic settings (Cebu, Philippines, and Kamphaeng Phet, Thailand), which included long-term follow-up of individuals (mean follow-up of 8.8, 1.9, and 5.0 y). These data allowed us to elucidate age-specific patterns of infection and immunity, and to quantify individual long-term antibody titer dynamics following infection. We formulated mathematical models to explain these patterns, allowing for the possibility of progressive loss of immunity to homotypic reinfection. At the individual level, we found that, in the absence of subsequent infection, antibody titers exhibit a steady long-term decay following incident infections (half-life of 7 to 8 y), with the rate of decay slowing with increasing age. At the population level, incorporating homotypic reinfection was required to explain the age-specific dynamics of infection and immunity observed in our cohorts. We estimated that in highly endemic settings such as the Philippines, 60% of individuals have been homotypically reinfected by the age of 40 y. Our findings highlight homotypic reinfections as a key feature of endemic DENV settings and suggest that vaccines mimicking natural infection might not be expected to provide lifelong protection against infection.


  • Open Access

    Immune-mediated protection and enhancement of dengue drives patterns of infant cases in Brazil

    by Matt D. T. Hitchings, Angkana T. Huang, Otavio T. Ranzani, Bernardo García-Carreras, Mauricio L. Nogueira, Albert I. Ko, Julio Croda, Henrik Salje, Derek A. T. Cummings

    Infants represent a vulnerable population for severe outcomes from infectious diseases. For dengue virus, maternal antibodies can cause severe disease in infants aged 5-12 months through antibody-dependent enhancement, but the role of maternal immunity in neonates aged 0-30 days has not been quantified. Our study leverages the re-emerging setting of Brazil, where the proportion of mothers with anti-dengue antibodies varies across space and time. Infant dengue burden has risen 11-fold from 2000-2024, in line with expansion in the general population. We fit mechanistic models to infant dengue and severe dengue cases reported through surveillance to disentangle the competing roles of maternal immunity, transmission, and age on the risk of dengue and severe dengue in infants across the first year of life. We observed peaks in severe dengue risk in neonates and at 7-8 months of age. These two peaks were explained by competing mechanisms. Infants born to seropositive mothers had lower overall risk of dengue, but increased risk of severe disease from 5-12 months, than those born to seronegative mothers. As dengue incidence increases, and vaccination becomes available, maternal antibodies may decrease infant burden but increase the risk of severe disease.


  • Open Access

    Linking multiple serological assays to infer dengue virus infections from paired samples using mixture models

    by Marco Hamins-Puértolas, Darunee Buddhari, Henrik Salje, Angkana T. Huang, Taweewun Hunsawong, Derek A.T. Cummings, Stefan Fernandez, Aaron Farmer, Surachai Kaewhiran, Direk Khampaen, et al.

    Dengue virus (DENV) is an increasingly important human pathogen, with already half of the globe’s population living in environments with transmission potential. Since many cases are missed by direct detection methods (RT-PCR or antigen tests), serological assays play an important role in the diagnostic process. However, individual assays can suffer from low sensitivity and specificity and interpreting results from multiple assays remains challenging, particularly because interpretations from multiple assays may differ, creating uncertainty over how to generate finalized interpretations. We develop a Bayesian mixture model that can jointly model data from multiple paired serological assays, to infer infection events. We first test the performance of our model using simulated data. We then apply our model to 677 pairs of acute and convalescent serum collected as a part of illness and household investigations across two longitudinal cohort studies in Kamphaeng Phet, Thailand, including data from 232 RT-PCR confirmed infections (gold standard). We compare the classification of the new model to prior standard interpretations that independently utilize information from either the hemagglutination inhibition assay (HAI) or the enzyme-linked immunosorbent assay (EIA). We find that additional serological assays improve accuracy of infection detection for both simulated and real world data. Models incorporating paired IgG and IgM data as well as those incorporating IgG, IgM, and HAI data consistently have higher accuracy when using PCR confirmed infections as a gold standard (87–90% F1 scores, a combined metric of sensitivity and specificity) than currently implemented cut-point approaches (82–84% F1 scores). Our results provide a probabilistic framework through which multiple serological assays across different platforms can be leveraged across sequential serum samples to provide insight into whether individuals have recently experienced a DENV infection. These methods are applicable to other pathogen systems where multiple serological assays can be leveraged to quantify infection history.


  • Open Access

    Reconciling heterogeneous dengue virus infection risk estimates from different study designs

    by Angkana T. Huang, Darunee Buddhari, Surachai Kaewhiran, Sopon Iamsirithaworn, Direk Khampaen, Aaron Farmer, Stefan Fernandez, Stephen J. Thomas, Isabel Rodriguez-Barraquer, Taweewun Hunsawong, et al.

    Uncovering rates at which susceptible individuals become infected with a pathogen, i.e., the force of infection (FOI), is essential for assessing transmission risk and reconstructing distribution of immunity in a population. For dengue, reconstructing exposure and susceptibility statuses from the measured FOI is of particular significance as prior exposure is a strong risk factor for severe disease. FOI can be measured via many study designs. Longitudinal serology is considered gold standard measurements, as they directly track the transition of seronegative individuals to seropositive due to incident infections (seroincidence). Cross-sectional serology can provide estimates of FOI by contrasting seroprevalence across ages. Age of reported cases can also be used to infer FOI. Agreement of these measurements, however, has not been assessed. Using 26 y of data from cohort studies and hospital-attended cases from Kamphaeng Phet province, Thailand, we found FOI estimates from the three sources to be highly inconsistent. Annual FOI estimates from seroincidence were 1.75 to 4.05 times higher than case-derived FOI. Seroprevalence-derived was moderately correlated with case-derived FOI (correlation coefficient = 0.47) with slightly lower estimates. Through extensive simulations and theoretical analysis, we show that incongruences between methods can result from failing to account for dengue antibody kinetics, assay noise, and heterogeneity in FOI across ages. Extending standard inference models to include these processes reconciled the FOI and susceptibility estimates. Our results highlight the importance of comparing inferences across multiple data types to uncover additional insights not attainable through a single data type/analysis.


  • Open Access

    A systematic review of using population-level human mobility data to understand SARS-CoV-2 transmission

    by Natalya Kostandova, Catherine Schluth, Rohan Arambepola, Fatumah Atuhaire, Sophie Bérubé, Taylor Chin, Eimear Cleary, Oscar Cortes-Azuero, Bernardo García-Carreras, Kyra H. Grantz, et al.

    The emergence of SARS-CoV-2 into a highly susceptible global population was primarily driven by human mobility-induced introduction events. Especially in the early stages, understanding mobility was vital to mitigating the pandemic prior to widespread vaccine availability. We conducted a systematic review of studies published from January 1, 2020, to May 9, 2021, that used population-level human mobility data to understand SARS-CoV-2 transmission. Of the 5505 papers with abstracts screened, 232 were included in the analysis. These papers focused on a range of specific questions but were dominated by analyses focusing on the USA and China. The majority included mobile phone data, followed by Google Community Mobility Reports, and few included any adjustments to account for potential biases in population sampling processes. There was no clear relationship between methods used to integrate mobility and SARS-CoV-2 data and goals of analysis. When considering papers focused only on the estimation of the effective reproductive number within the US, there was no clear relationship identified between this measure and changes in mobility patterns. Our findings underscore the need for standardized, systematic ways to identify the source of mobility data, select an appropriate approach to using it in analysis, and reporting.


  • Open Access

    Reconciling heterogeneous dengue virus infection risk estimates from different study designs

    by Angkana T. Huang, Darunee Buddhari, Surachai Kaewhiran, Sopon Iamsirithaworn, Direk Khampaen, Aaron Farmer, Stefan Fernandez, Stephen J. Thomas, Isabel Rodriguez Barraquer, Taweewun Hunsawong, et al.

    Uncovering rates at which susceptible individuals become infected with a pathogen, i.e. the force of infection (FOI), is essential for assessing transmission risk and reconstructing distribution of immunity in a population. For dengue, reconstructing exposure and susceptibility statuses from the measured FOI is of particular significance as prior exposure is a strong risk factor for severe disease. FOI can be measured via many study designs. Longitudinal serology are considered gold standard measurements, as they directly track the transition of seronegative individuals to seropositive due to incident infections (seroincidence). Cross-sectional serology can provide estimates of FOI by contrasting seroprevalence across ages. Age of reported cases can also be used to infer FOI. Agreement of these measurements, however, have not been assessed. Using 26 years of data from cohort studies and hospital-attended cases from Kamphaeng Phet province, Thailand, we found FOI estimates from the three sources to be highly inconsistent. Annual FOI estimates from seroincidence was 2.46 to 4.33-times higher than case-derived FOI. Correlation between seroprevalence-derived and case-derived FOI was moderate (correlation coefficient=0.46) and no systematic bias. Through extensive simulations and theoretical analysis, we show that incongruences between methods can result from failing to account for dengue antibody kinetics, assay noise, and heterogeneity in FOI across ages. Extending standard inference models to include these processes reconciled the FOI and susceptibility estimates. Our results highlight the importance of comparing inferences across multiple data types to uncover additional insights not attainable through a single data type/analysis. Significance statement Dengue virus infections are surging globally. Knowing who, where, and how many people are at risk of infection is crucial in determining means to protect them. Here, we compare three current approaches in measuring risk (two involving blood samples and one involving case counts) to estimate the risk of infection. Estimates derived from each method differed greatly. By accounting for rise and falls of antibodies following infections, noise in the antibody titer measurements, and heterogeneity in infection risk across ages, we reconciled the measurements. As measurements from blood samples and case counts are pillars in uncovering risk of most infectious diseases, our results signifies integrating these processes into risk measurements of pathogens beyond dengue virus.